Assuntos
Enterovirus Humano B/patogenicidade , Infecções por Enterovirus/etiologia , Síndrome de Guillain-Barré/etiologia , Turismo Médico , Terapia Viral Oncolítica/efeitos adversos , Adenocarcinoma/secundário , Adenocarcinoma/terapia , Doadores de Sangue , Infecções por Enterovirus/transmissão , Síndrome de Guillain-Barré/virologia , Humanos , Hospedeiro Imunocomprometido , Letônia , Masculino , Minnesota , Neoplasias Pancreáticas/terapiaRESUMO
Patients with secondary acute myeloid leukemia (sAML) arising from prior myelodysplastic syndromes have poor prognosis. Anthracycline plus cytarabine (7 + 3) is a standard treatment option for patients who are fit for intensive therapy. In the present study, 22 of 96 sAML patients (23 %) were treated with 7 + 3 and achieved median overall survival (OS) of 9.8 months. Hypomethylating agents (HMA) were given for MDS in 6/22 (28 %) of the patients. When evaluating the prior HMA group, CR/CRi was 50 % for those with prior HMA exposure and 63 % for those without HMA exposure (P = 0.6). Median OS was 14 months for prior HMA exposure vs 10 months for no prior HMA (P = 0.9). The outcome of sAML patients who were treated with 7 + 3 continues to be poor. No statistical significant difference was found between response rates and mOS between prior HMA exposure or not. Additional larger studies are needed to confirm our results.